July 1, 1996Journal of Cardiovascular Electrophysiology
Antiarrhythmic Drug Therapy for Ventricular Arrhythmias: Current Perspectives
Population
Patients with ventricular arrhythmias, particularly those with underlying structural heart disease at high…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Reinforces caution with antiarrhythmic drugs in high-risk patients; leaves open optimal selection strategies for randomized evaluation.
Key Points
- This research focuses on understanding the effectiveness and risks of antiarrhythmic drug therapy in patients with ventricular arrhythmias.
- Review of recent retrospective and prospective randomized trial data on antiarrhythmic therapy.
- Assessment of total mortality as a major endpoint for pharmacologic interventions.
- Evaluation of the impact of structural heart disease on arrhythmia prognosis.
- Antiarrhythmic drugs may prevent sudden death and improve symptoms but may also lead to excess mortality.
- Recent data emphasize a need to refine the classification of antiarrhythmic agents.
- Clinical trials are ongoing to assess the risks and benefits of new antiarrhythmic therapies.
Structured PICO
P
Population
Patients with ventricular arrhythmias, particularly those with underlying structural heart disease at high risk for sudden death
I
Intervention
Antiarrhythmic drug therapy
O
Outcome
Prevention of sudden death, reduction in total mortality, or improvement in symptoms
This review emphasizes the need to carefully weigh the risks and benefits of antiarrhythmic drugs for ventricular arrhythmias, given the potential for excess mortality.
Cite This Study
Link et al. (1996) studied this question.